These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 9116559)
1. Treatment for haemophilia by postcode. Ludlam CA; Hay CR; Dolan G BMJ; 1997 Mar; 314(7082):749. PubMed ID: 9116559 [No Abstract] [Full Text] [Related]
3. Haemophilia care within the United Kingdom. Ludlam CA Haemophilia; 1998 Jul; 4(4):427-8. PubMed ID: 9873769 [No Abstract] [Full Text] [Related]
4. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Mannucci PM Blood Transfus; 2010 Oct; 8(4):288-91. PubMed ID: 20967171 [No Abstract] [Full Text] [Related]
5. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Franchini M Blood Transfus; 2010 Oct; 8(4):292-6. PubMed ID: 20967172 [No Abstract] [Full Text] [Related]
6. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR; Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203 [No Abstract] [Full Text] [Related]
7. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation. Ludlam CA Lancet; 1998 Apr; 351(9111):1289-90. PubMed ID: 9643779 [No Abstract] [Full Text] [Related]
8. Haemophilia and AIDS. Bloom AL Lancet; 1985 Feb; 1(8424):336. PubMed ID: 2857381 [No Abstract] [Full Text] [Related]
10. Recombinant factor VIII: are we really getting more for less? Gorlin JB; Ewenstein BM J Pediatr; 1997 Apr; 130(4):507-9. PubMed ID: 9108841 [No Abstract] [Full Text] [Related]
11. Letter: Treatment of haemophilia. Blackburn EK Lancet; 1974 Jul; 2(7872):105. PubMed ID: 4137023 [No Abstract] [Full Text] [Related]
12. The current status of recombinant human factor VIII. Aronson DL Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131 [No Abstract] [Full Text] [Related]
13. Design of clinical studies with recombinant factor VIII. The rFactor VIII Clinical Trial Group. Pennington JE; Schwartz RS Semin Hematol; 1991 Apr; 28(2 Suppl 1):27-8. PubMed ID: 1908123 [No Abstract] [Full Text] [Related]
14. Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group. Walker I; Poon MC Lancet; 1992 Jan; 339(8784):61-2. PubMed ID: 1345984 [No Abstract] [Full Text] [Related]
15. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. White GC; McMillan CW; Kingdon HS; Shoemaker CB N Engl J Med; 1989 Jan; 320(3):166-70. PubMed ID: 2492083 [No Abstract] [Full Text] [Related]
16. Pioneering therapeutic proteins in hemophilia care through innovative technologies. Pabinger-Fasching I; Négrier C Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062 [No Abstract] [Full Text] [Related]
18. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Hsu HC; Chen YF; Ho CH Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180 [TBL] [Abstract][Full Text] [Related]
20. Modern treatment of hemophilia: from the shadows towards the light. Mannucci PM Thromb Haemost; 1993 Jul; 70(1):17-23. PubMed ID: 8236096 [No Abstract] [Full Text] [Related] [Next] [New Search]